10Apr
April 2018
Cabinet Barny advised Domain Therapeutics on the assignment of its intellectual property rights towards Foliglurax in the course of Lundbeck's acquisition of Prexton Therapeutics.
Cabinet Barny advised Domain Therapeutics on the assignment of its intellectual property rights towards Foliglurax in the course of Lundbeck's acquisition of Prexton Therapeutics.